At Radisens Diagnostics, we're building the next generation of portable diagnostic platforms and consumable assay panels. Find out about this high growth decentralised diagnostics marketplace, or learn more about our disruptive technology.
For Investors
No other solution on the market delivers on the unmet clinical need to integrate three families of blood testing (namely immunoassay, chemistry and haematology) into a single device, which is required to realise significant cost savings sought by managed care organizations and deliver the economies of scale for small-medium physician office labs. There is a clear unmet market need for a single connected sample-to-answer device with integrated quality controls, to address this US$6bn (5-8% CAGR) point-of-care niche. Radisens' significant early market traction and revenue generating strategic partnerships is testament to our disruptive patent-pending technology, extensive IP portfolio and unique value proposition.
The Technology
Radisens' disruptive diagnostics platform comprises a connected multi-fluorescent device, centrifugal microfluidic mini-disc consummables where upon multiplexed assays run in a sample-to-answer panel. Initial multiplexed panels provide for the long-term patient management of chronic diseases, including multiplexed renal, chronic kidney, diabetes, heart disease and hypertension panels. With the full assay integrated onto the low-cost mini-disc, the clinician simply applies a finger-prick of blood, loads the mini-disc into the device, for results within minutes. Real-time connectivity ensures seamless updating of the patients electronic health record. Embedded controls minimize quality assurance overheads and eliminate user-induced errors.
Latest News
- Positions Open: Development Scientists – Clinical Chemistry
- Radisens to compete in IBM SmartCamp London and launches BES investment fund
- Radisens Diagnostics Announces €1M Contract with European Space Agency
- NHS contracts Radisens Diagnostics to develop kidney test
- Radisens appoints Neil Butler as Non-Executive Director
- Kernel leads €1.1m investment in Radisens Diagnostics
- Radisens to speak at NHS Conference
- Radisens wins regional Seedcorn Competition and launches BES Funding round
- French Angel Fund invests in Radisens